🔴 Pyxis Oncology is trading 19.31% down today after pricing a $110 million public offering

Pyxis Oncology is trading 19.31% lower at $2.34 after pricing a public offering expected to raise approximately $110 million.

• The deal pairs shares or pre-funded warrants with warrants to purchase additional shares; common-stock units are priced at $2.90.
• Full warrant exercise could bring total gross proceeds to approximately $282.6 million.
• Proceeds are intended to advance MICVO, support its planned Phase 3 trial and fund general corporate purposes; broader market context showed no comparable drop.